nach oben

Erschienen in:

01.09.2014 | Original Article

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype

verfasst von: Mieke Van Bockstal, Kathleen Lambein, Hannelore Denys, Geert Braems, Ann Nuyts, Rudy Van den Broecke, Veronique Cocquyt, Olivier De Wever, Louis Libbrecht

Erschienen in: Virchows Archiv | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to characterize ductal carcinoma in situ (DCIS) according to human epidermal growth factor receptor 2 (HER2) amplification status and molecular subtype. In addition, we performed a detailed HER2 and CEP17 copy number analysis and we assessed the impact of recent changes in the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on HER2 immunohistochemical (IHC) scores in DCIS. Nuclear grade, extensive comedonecrosis, stromal architecture, stromal inflammation, and progesterone receptor (PR) expression were significantly associated with HER2 amplification status. In multivariate analysis, stromal inflammation and extensive comedonecrosis were the only two features that remained significantly related to HER2 amplification status. The recent changes in ASCO/CAP guidelines resulted in significant upgrading of HER2 IHC score. Remarkably, about one in five non-amplified DCIS presented a 3+ IHC score, regardless of the scoring method. The biological significance of this phenomenon is presently unknown. After categorization according to molecular subtype, luminal A DCIS mainly presented histopathological features associated with good prognosis, whereas luminal B/HER2+ and HER2+ categories displayed a more aggressive phenotype. Overall, our results demonstrate that HER2-amplified DCIS constitute a clearly distinct subgroup which is characterized by histopathological features associated with poor prognosis. Further studies are required to elucidate the biological significance of a 3+ IHC score in non-amplified DCIS, as well as its mechanism.

Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL (1992) Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 23:974–979PubMedCrossRef

Altintas S, Lambein K, Huizing MT, Braems G, Tjin Asjoe F, Hellemans H, Van Marck E, Weyler J, Praet M, Van den Broecke R, Vermorken JB, Tjalma WA (2009) Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J 15:120–132PubMedCrossRef

Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR (1992) Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28:644–648PubMedCrossRef

Bijker N, Donker M, Wesseling J, den Heeten GJ, Rutgers EJ (2013) Is DCIS breast cancer, and how do I treat it? Curr Treat Options Oncol 14:75–87. doi:10.1007/s11864-012-0217-1 PubMedCrossRef

Burkhardt L, Grob TJ, Hermann I, Burandt E, Choschzick M, Janicke F, Muller V, Bokemeyer C, Simon R, Sauter G, Wilczak W, Lebeau A (2010) Gene amplification in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 123:757–765. doi:10.1007/s10549-009-0675-8 PubMedCrossRef

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750. doi:10.1093/jnci/djp082 PubMedCentralPubMedCrossRef

Clark SE, Warwick J, Carpenter R, Bowen RL, Duffy SW, Jones JL (2011) Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer 104:120–127. doi:10.1038/sj.bjc.6606021 PubMedCentralPubMedCrossRef

Claus EB, Chu P, Howe CL, Davison TL, Stern DF, Carter D, DiGiovanna MP (2001) Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol 70:303–316. doi:10.1006/exmp.2001.2366 PubMedCrossRef

Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD (2011) Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21–29. doi:10.1016/s1470-2045(10)70266-7 PubMedCrossRef

10.

Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56–62PubMedCrossRef

11.

Giordano C, Vizza D, Panza S, Barone I, Bonofiglio D, Lanzino M, Sisci D, De Amicis F, Fuqua SA, Catalano S, Ando S (2013) Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol 7:379–391. doi:10.1016/j.molonc.2012.11.002 PubMedCrossRef

12.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel M (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223. doi:10.1093/annonc/mdt303 PubMedCentralPubMedCrossRef

13.

Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC, American Society of Clinical O, College of American P (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–e72. doi:10.1043/1543-2165-134.7.e48 PubMed

14.

Han K, Nofech-Mozes S, Narod S, Hanna W, Vesprini D, Saskin R, Taylor C, Kong I, Paszat L, Rakovitch E (2012) Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol 24:183–189. doi:10.1016/j.clon.2011.09.008 CrossRef

15.

Harvey JM, Clark GM, Osborne CK, Allred DC (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed

16.

Holmes P, Lloyd J, Chervoneva I, Pequinot E, Cornfield DB, Schwartz GF, Allen KG, Palazzo JP (2011) Prognostic markers and long-term outcomes in ductal carcinoma in situ of the breast treated with excision alone. Cancer 117:3650–3657. doi:10.1002/cncr.25942 PubMedCrossRef

17.

Hoorntje LE, Schipper MEI, Peeters PHM, Bellot F, Storm RK, Borel Rinkes IHM (2003) The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol 10:748–753. doi:10.1245/aso.2003.11.011 PubMedCrossRef

18.

Horimoto Y, Tokuda E, Arakawa A, Kosaka T, Saito M, Kasumi F (2011) Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res 167:e205–e210. doi:10.1016/j.jss.2009.07.030 PubMedCrossRef

19.

Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY (2012) FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Breast Cancer Res 14:R115. doi:10.1186/bcr3239 PubMedCentralPubMedCrossRef

20.

Kepple J, Henry-Tillman RS, Klimberg VS, Layeeque R, Siegel E, Westbrook K, Korourian S (2006) The receptor expression pattern in ductal carcinoma in situ predicts recurrence. Am J Surg 192:68–71. doi:10.1016/j.amjsurg.2006.04.002 PubMedCrossRef

21.

Kerlikowske K, Molinaro AM, Gauthier ML, Berman HK, Waldman F, Bennington J, Sanchez H, Jimenez C, Stewart K, Chew K, Ljung BM, Tlsty TD (2010) Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102:627–637. doi:10.1093/jnci/djq101 PubMedCentralPubMedCrossRef

22.

Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK (2012) Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst 104:1825–1836. doi:10.1093/jnci/djs446 PubMedCentralPubMedCrossRef

23.

Kulkarni S, Patil DB, Diaz LK, Wiley EL, Morrow M, Khan SA (2008) COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer 8:36. doi:10.1186/1471-2407-8-36 PubMedCentralPubMedCrossRef

24.

Lambein K, Praet M, Forsyth R, Van den Broecke R, Braems G, Matthys B, Cocquyt V, Denys H, Pauwels P, Libbrecht L (2011) Relationship between pathological features, HER2 protein expression and HER2 and CEP17 copy number in breast cancer: biological and methodological considerations. J Clin Pathol 64:200–207. doi:10.1136/jcp.2010.084863 PubMedCrossRef

25.

Lambein K, Van Bockstal M, Denys H, Libbrecht L (2014) 2013 Update of the American Society of Clinical Oncology/College of American Pathologists guideline for human epidermal growth factor receptor 2 testing: impact on immunohistochemistry-negative breast cancers. J Clin Oncol. doi:10.1200/JCO.2013.54.2530 PubMed

26.

Lambein K, Van Bockstal M, Vandemaele L, Geenen S, Rottiers I, Nuyts A, Matthys B, Praet M, Denys H, Libbrecht L (2013) Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: clinical and pathobiological relevance. Am J Clin Pathol 140:561–566. doi:10.1309/AJCP4A7KTAYHZSOE PubMedCrossRef

27.

Latta EK, Tjan S, Parkes RK, O’Malley FP (2002) The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Mod Pathol 15:1318–1325. doi:10.1097/01.MP.0000038462.62634.B1 PubMedCrossRef

28.

Liao N, Zhang GC, Liu YH, Li XR, Yao M, Xu FP, Li L, Wu YL (2011) HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component. Pathol Res Pract 207:1–7. doi:10.1016/j.prp.2010.08.005 PubMedCrossRef

29.

Nofech-Mozes S, Spayne J, Rakovitch E, Kahn HJ, Seth A, Pignol JP, Lickley L, Paszat L, Hanna W (2008) Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol 2:7–18PubMedCentralPubMed

30.

Noh JM, Lee J, Choi DH, Cho EY, Huh SJ, Park W, Nam SJ, Lee JE, Kil WH (2013) HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. Breast 22:894–897. doi:10.1016/j.breast.2013.04.001 PubMedCrossRef

31.

Park K, Han S, Kim HJ, Kim J, Shin E (2006) HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 48:702–707. doi:10.1111/j.1365-2559.2006.02403.x PubMedCrossRef

32.

Perez EA, Reinholz MM, Hillman DW, Tenner KS, Schroeder MJ, Davidson NE, Martino S, Sledge GW, Harris LN, Gralow JR, Dueck AC, Ketterling RP, Ingle JN, Lingle WL, Kaufman PA, Visscher DW, Jenkins RB (2010) HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol 28:4307–4315. doi:10.1200/JCO.2009.26.2154 PubMedCentralPubMedCrossRef

33.

Pinder SE, Duggan C, Ellis IO, Cuzick J, Forbes JF, Bishop H, Fentiman IS, George WD, Party UKCCoCRDCISW (2010) A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer 103:94–100. doi:10.1038/sj.bjc.6605718 PubMedCentralPubMedCrossRef

34.

Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M (2012) Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, van de Vijver MJ (eds) World Health Organization classification of tumours. WHO Press, Geneva, pp 95–97

35.

Punglia RS, Schnitt SJ, Weeks JC (2013) Treatment of ductal carcinoma in situ after excision: would a prophylactic paradigm be more appropriate? J Natl Cancer Inst 105:1527–1533. doi:10.1093/jnci/djt256 PubMedCrossRef

36.

Qian L, Chen L, Shi M, Yu M, Jin B, Hu M, Xia Q, Zhang X, Shen B, Guo N (2006) A novel cis-acting element in Her2 promoter regulated by Stat3 in mammary cancer cells. Biochem Biophys Res Commun 345:660–668. doi:10.1016/j.bbrc.2006.04.153 PubMedCrossRef

37.

Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, Spayne J, Taylor C, Paszat L (2012) HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 106:1160–1165. doi:10.1038/bjc.2012.41 PubMedCentralPubMedCrossRef

38.

Rauch GM, Kuerer HM, Scoggins ME, Fox PS, Benveniste AP, Park YM, Lari SA, Hobbs BP, Adrada BE, Krishnamurthy S, Yang WT (2013) Clinicopathologic, mammographic, and sonographic features in 1,187 patients with pure ductal carcinoma in situ of the breast by estrogen receptor status. Breast Cancer Res Treat 139:639–647. doi:10.1007/s10549-013-2598-7 PubMedCentralPubMedCrossRef

39.

Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, Fox KR, Zhang PJ, Czerniecki BJ (2009) HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev 18:1386–1389. doi:10.1158/1055-9965.EPI-08-1101 PubMedCentralPubMedCrossRef

40.

Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF (2009) Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27:1323–1333. doi:10.1200/JCO.2007.14.8197 PubMedCrossRef

41.

Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED, Lewinsky B, Gamagami P, Slamon DJ (1995) Prognostic classification of breast ductal carcinoma-in-situ. Lancet 345:1154–1157PubMedCrossRef

42.

Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N (2013) Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat 142:415–421. doi:10.1007/s10549-013-2755-z PubMedCrossRef

43.

Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67. doi:10.1186/bcr2128 PubMedCentralPubMedCrossRef

44.

Van Bockstal M, Lambein K, Gevaert O, De Wever O, Praet M, Cocquyt V, Van den Broecke R, Braems G, Denys H, Libbrecht L (2013) Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast. Histopathology 63:520–533. doi:10.1111/his.12188

45.

Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N (2011) Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478–488. doi:10.1093/jnci/djr027 PubMedCentralPubMedCrossRef

46.

Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF, American Society of Clinical O, College of American P (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013. doi:10.1200/JCO.2013.50.9984 PubMedCrossRef

47.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical O, College of American P (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145. doi:10.1200/JCO.2006.09.2775 PubMedCrossRef

48.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H (2003) Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases. Pathol Int 53:422–428PubMedCrossRef

Titel: Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype
verfasst von: Mieke Van Bockstal
Kathleen Lambein
Hannelore Denys
Geert Braems
Ann Nuyts
Rudy Van den Broecke
Veronique Cocquyt
Olivier De Wever
Louis Libbrecht
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 3/2014
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-014-1609-3

Springer Medizin

Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype

Abstract

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2014

Podoplanin expression in the cyst wall correlates with the progression of intraductal papillary mucinous neoplasm

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers

Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma

Frequency and clinicopathological features of fibroelastotic changes in the gastrointestinal tract

Increased lymphangiogenesis in Riedel thyroiditis (Immunoglobulin G4-related thyroid disease)

SPARC/osteonectin is involved in metastatic process to the lung during melanoma progression

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie